Avadel Pharmaceuticals plc

AVDL

IE00BDGMC594

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:05 2024-07-12 pm EDT			5-day change	1st Jan Change
16.59 ^USD	+0.91%		+12.25%	+16.43%

Jul. 01	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell Small Cap Completeness Index	CI
Jul. 01	Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2000 Index	CI

Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2500 Growth Index

July 30, 2024

Latest news about Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell Small Cap Completeness Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2000 Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 3000E Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 3000 Growth Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 3000E Growth Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2000 Growth Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2000 Dynamic Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2500 Growth Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2500 Index	Jun. 30	CI
Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 3000 Index	Jun. 30	CI
Avadel Pharmaceuticals to Join Russell 3000 Index Monday; Shares Rise After Hours	Jun. 27	MT
Transcript : Avadel Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM	Jun. 12
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	Jun. 05	MT
Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension Data at Sleep 2024	May. 22	CI
Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors	May. 21	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	May. 14	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	May. 10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Avadel Pharmaceuticals Q1 Loss Narrows	May. 08	MT
Avadel Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Transcript : Avadel Pharmaceuticals plc, Q1 2024 Earnings Call, May 08, 2024	May. 08
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT

Chart Avadel Pharmaceuticals plc

Duration

Period

More charts

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Avadel Pharmaceuticals plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.59 USD

Average target price

23.65 USD

Spread / Average Target

+42.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AVADEL PHARMACEUTICALS PLC	+16.43%	1.58B
ELI LILLY AND COMPANY	+62.66%	841B
NOVO NORDISK A/S	+40.42%	625B
JOHNSON & JOHNSON	-4.37%	360B
MERCK & CO., INC.	+17.16%	327B
ABBVIE INC.	+9.87%	300B
ASTRAZENECA PLC	+15.66%	242B
NOVARTIS AG	+17.90%	227B
AMGEN INC.	+14.86%	174B
PFIZER, INC.	+0.45%	162B

Other Pharmaceuticals